Supreme Court: FDA Approval Doesn't Bar Suits

BY ALICIA AULT

n an eagerly anticipated opinion, the U.S. Supreme Court has upheld a lower court ruling that Food and Drug Administration approval does not give pharmaceutical companies immunity from product liability lawsuits.

The justices voted 6-3 to affirm the judgment of the Vermont Supreme Court that federal law did not preempt

Diana Levine's claim of inadequate warning on the label of promethazine (Phenergan). Ms. Levine received the drug by intravenous push and subsequently lost her arm. She was awarded \$6.7 million by a Vermont jury.

A majority of justices rejected the argument by Wyeth Pharmaceuticals Inc., which manufactures Phenergan, that it was impossible for the company to simultaneously comply with both federal and state laws and regulations.

Wyeth could have unilaterally strengthened the label at any time without input or clearance from the FDA, wrote the justices, concurring with the lower court opinion. And the company's argument that following the duty to warn under state law would have interfered with the FDA's power to preempt state law was "meritless," according to the majority opinion.

Justice Clarence Thomas voted with the majority, agreeing that Wyeth could have changed its label and complied with both state and federal laws. But he said that he did not agree with the majority's more far-reaching conclusions about preemption, specifically a tendency to override state laws when they were perceived to be an impediment to enforcing federal statutes.

Justice Samuel Alito and Justice Antonin Scalia, joined by Chief Justice John Roberts, dissented, writing in their opinion that "this case illustrates that tragic facts make bad law. The Court holds that a state tort jury, rather than the Food and Drug Administration, is ultimately responsible for regulating warning labels for prescription drugs." That premise is not consistent with previous rulings, they wrote.

Indeed, just last year the U.S. Supreme Court ruled in Riegel v. Medtronic Inc. that FDA approval conferred special protection against product liability suits involving medical devices.

Consumer advocacy group Public Citizen called the ruling a broad rebuff to the industry's attempt to duck tort damages. Brian Wolfman, director of Public Citizen Litigation Group, said that the organization was "extremely gratified" that the Court "upheld the traditional right of patients harmed by defective and mislabeled drugs to sue drug companies to recover compensation for their injuries."■

SAVE THE DATE! REGISTER TODAY FOR THIS EXCITING SCIENTIFIC PROGRAM

To register or for more information, visit www.sdefderm.com



SKIN DISEASE EDUCATION FOUNDATION presents

COSMETIC DERMATOLOGY SEMINAR 2009™


A CONTINUING MEDICAL EDUCATION CONFERENCE

May 28-31, 2009 Loews Santa Monica Beach Hotel


Learn the latest in cosmetic dermatology and get up-to-date on recent breakthroughs in therapeutic treatments and cosmetic surgery. An outstanding faculty, representing the best in the field, will cover the newest techniques, scientific therapies and research focused on improving patient care and enhancing your practice.

Featuring:

- Facial Rejuvenation: The Best Techniques and Devices
- Body Contouring: Assessing What Really Works
- Botulinum Toxins: Does it Matter Which One you Use?









www.sdefderm.com

MEDICAL DIRECTORS:



David J. Goldberg, MD, JD Clinical Professor, Mount Sinai School of Medicine Director, Skin Laser & Surgery Specialists of NY/NJ New York, NY



Christopher B. Zachary, MBBS, FRCP Professor and Chair, Department of Dermatology University of California, Irvine, CA

The opinions expressed at Skin Disease Education Foundation seminars do not necessarily reflect those of Skin Disease Education Foundation, Elsewier Inc. or the supporters of the seminars. Elsewier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in recorrections; activation and control of the contr presentations, including any claims related to the products, drugs or services mentioned.

Jointly sponsored by





INDEX OF **ADVERTISERS**

Abbott Laboratories TriLipix 29-32 Accera. Inc. Alcon, Inc. 33-34 Audio-Digest Boehringer Ingelheim Pharmaceuticals, Inc. 25-26 Eisai Inc. and Pfizer Inc. Aricept **Endo Pharmaceuticals** 14-16 Forest Laboratories, Inc. 21-24 Lexapro Namenda 26a-26b King Pharmaceuticals, Inc. 36a-36b Merck & Co., Inc. Novo Nordisk Inc. NovoLog Corporate 11-12 Pfizer Inc. 3-4 Purdue Pharma L.P. Rexall Sundown, Inc. Osteo Bi-Flex 10 Takeda Pharmaceuticals America, Inc. Wyeth Pharmaceuticals Inc. 43-44 Corporate